Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program

/PRNewswire/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in...

Related Keywords

State Of California ,California ,United States ,San Diego ,Canada ,Vancouver ,British Columbia , ,Research Advisory Board ,Instagram ,Twitter ,Nova Mentis Life Science Corp ,United States Drug Enforcement Agency ,European Union ,Facebook ,Us Food Drug Administration ,Mentis Life Science ,Mycrodose Therapeutics ,Fragilex Syndrome ,Autism Spectrum Disorder ,Will Rascan ,Chief Executive Officer ,Southern California ,Joint Venture ,Mycrodose Therapeutic ,Schedulei License ,California Attorney General ,Drug Administration ,Cannabis ,Biotechnology ,Health Care Amp Hospitals ,